We report that interference with the cholesterol assay using the cholesterol oxidase: p-aminophenazone method which is observed during lipoprotein preparation, is caused by the anti-bacterial agent thimerosol used in the preparation. We suggest that an alternative anti-bacterial agent should be used in these circumstances.
Thimerosal (ethylmercurithiosalicylic acid, sodium salt), added as an anti-bacterial agent to salt solutions used for the isolation of serum lipoproteins by sequential ultracentrifugation, has been shown to interfere with cholesterol estimation by the cholesterol oxidase-paminophenazone method (CHOD-PAP, Boehringer Mannheim GmbH, Mannheim, West Germany). The interference was first noted in assays of the cholesterol contents of isolated lipoprotein fractions, all of which were markedly lower than corresponding values by the Boehringer catalase method. Since previous work has demonstrated that the two methods give identical results for serum cholesterol concentration, attention was turned to the components of the salt solutions used in preparative ultracentrifugation.
Reagents and methods
Initially, three solutions were investigated:
A. Solution for isolation of very low density lipoproteins (d = 1·005 at 26°q, containing sodium chloride (11,74 gil, Analar grade, BDH Chemicals Ltd, Poole, Dorset), thimerosal (100 mg/l, Sigma London Chemical Co. Ltd, Poole, Dorset) and ethylenediaminetetra-acetic acid, sodium salt (EDTA, 100 mg/l, Analar grade, BDH Chemicals Ltd).
B. Solution for isolation of high density lipoproteins (d = 1·21 at 26°q, containing sodium bromide (288 gil, analytical reagent grade, Mallinckrodt Inc, St Louis, Mo., USA) dissolved in solution A.
C. Aqueous sodium chloride (150 mmol/l, Analar grade, BDH Chemicals Ltd). Subse-146 quently, components were omitted from solution A or added to solution C.
For analyses of cholesterol contents by the CHOD-PAP method, 100 IJ.I aliquots of serum diluted 1:9 with the above solutions or variants thereof were added to 1 ml of the composite reagent and processed according to the manufacturer's directions. Absorbances were read at 500 nm in cuvettes of 1·5 ml capacity with an optical path length of 10 mm.
Throughout, reference values were provided by dilutions in saline (solution C). All results were calculated in terms of the original serum concentration, due allowance being made for the slightly different dilution factor involved compared with that in the manufacturer's recommendations. Values in Table 1 and in the text are expressed as mean ± standard deviation.
Results
Estimates obtained from dilutions in solution B of 11 serum specimens with reference values ranging from 3·10 to 7·66 mmol/l were demonstrably low (Table 1, row 1) . The mean of the individual percentage decrements was 27 ± 9% and Student's paired t-test showed a high level of significance (P<O·OOI). Similar results were evident in a smaller series involving dilutions of three serum specimens in solution A (Table 1, row 2). The mean of the individual percentage decrements in the reference values, which were 5·39, 5·89 and 7·82 mmol/l, was 45 ± 8%.
These results indicated that the lowering effect in solution B could not be ascribed to the presence of sodium bromide, the only compo- nent present other than those in solution A. This was confirmed by a series involving 24 estimates of serum dilutions in solution C supplemented with the same concentration of sodium bromide as in solution B, viz. 288 gil (Table 1 , row 3). In this series, the range of reference values was 3·00--8·48 mmol/l. The paired r-test gave a value of P > 0·4. .
Of the two remaining common components of solutions A and B, viz. EDTA and thimerosal, the widespread use of the former as an anticoagulant in blood specimens taken for plasma collection suggested that any adverse effect would have been already noted. Accordingly, attention focussed upon thimerosal as the probable cause of the interference. This was shown to be the case by two experiments involving, in the first, omission of thimerosal from solution A, and in the second, its addition to solution C.
Thimerosal was omitted from solution A in a series involving 15 serum specimens with reference values between 2·83 and 7·91 mmol/l, The results confirmed that EDTA had no adverse effect on the method (Table 1, row 4) . The value for P in the paired t-test was greater than 0·5. In contrast, dilution of 14 serum specimens in solution C supplemented with thimerosal at the same concentration as in solutions A and B produced an appreciable lowering of the reference values, which in this series ranged from 3·23 to 8·06 mmol/l (Table 1, row 5). The mean of the individual percentage decrements was 48 ± 11%, and the paired t-test gave a highly significant result (P<O·OOI).
Substitution of sodium azide for thimerosal in solution A, at the same concentration, indicated no adverse effect on the CHaD-PAP assays in a series involving eight serum specimens with reference values between 4·76 and 7·27 mmol/l (Table 1, row 6). In the paired t-test, the value of P was greater than O·R
Conclusion
Thimerosal causes appreciable lowering of cholesterol estimates by the Boehringer CHOD-PAP method. It is recommended that it should be replaced by sodium azide as an anti-bacterial agent in solutions used for the isolation of lipoproteins by sequential preparative ultracentrifugation.
